Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Scynexis Inc (SCYX)

Scynexis Inc (SCYX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 26,459
  • Shares Outstanding, K 41,965
  • Annual Sales, $ 3,750 K
  • Annual Income, $ -21,290 K
  • EBIT $ -35 M
  • EBITDA $ -33 M
  • 60-Month Beta 1.37
  • Price/Sales 7.06
  • Price/Cash Flow N/A
  • Price/Book 0.73
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.57
  • Most Recent Earnings $-0.17 on 11/05/25
  • Next Earnings Date 03/11/26
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Options Overview Details

View History
  • Implied Volatility 0.00% (unch)
  • Historical Volatility 49.64%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Expected Move (DTE 28) 0.0000 (0.00%)
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A
  • Expected Range 0.6305 to 0.6305

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.29
  • Number of Estimates 1
  • High Estimate 0.29
  • Low Estimate 0.29
  • Prior Year -0.09
  • Growth Rate Est. (year over year) +422.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6075 +2.06%
on 11/20/25
0.7300 -15.07%
on 11/21/25
+0.0300 (+5.08%)
since 11/19/25
3-Month
0.5650 +9.73%
on 11/17/25
1.1396 -45.59%
on 09/23/25
-0.5000 (-44.64%)
since 09/19/25
52-Week
0.5650 +9.73%
on 11/17/25
1.4900 -58.39%
on 01/02/25
-0.3900 (-38.61%)
since 12/19/24

Most Recent Stories

More News
SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK

GSK remains committed to the relaunch of BREXAFEMME, and following its relaunch, SCYNEXIS stands to receive up to $145.5 million in annual net sales milestones as well as royalties, net of payments to...

SCYX : 0.6230 (-1.19%)
Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections

Five-year grant of $7 million annually to the academic researchers is aimed at accelerating the development of new therapeutics to combat resistant fungal infections, including the Company’s next generation...

SCYX : 0.6230 (-1.19%)
Scynexis: Q3 Earnings Snapshot

Scynexis: Q3 Earnings Snapshot

SCYX : 0.6230 (-1.19%)
SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update

SCYNEXIS to receive one-time payments totalling $24.8 million from GSK as part of the resolution of the disagreement related to the restart of the Phase 3 MARIO study in invasive candidiasis. Scynexis...

SCYX : 0.6230 (-1.19%)
SCYNEXIS and GSK Amend License Agreement

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. SCYNEXIS...

SCYX : 0.6230 (-1.19%)
SCYNEXIS Announces Positive Results from a Phase 1, Single Ascending Dose and Multiple Ascending Dose Study of its Second-Generation Fungerp (SCY-247)

No safety concerns or dose limiting toxicities observed SCY-247 was able to achieve target exposures at doses lower than our first-generation fungerp Safety, tolerability, and pharmacokinetic...

SCYX : 0.6230 (-1.19%)
SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)

Oral presentation will feature data demonstrating SCY-247 in vitro activity against C. auris strains, including isolates with mutations commonly associated with echinocandin-resistance Additional...

SCYX : 0.6230 (-1.19%)
SCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conference September 8 – 10, 2025

JERSEY CITY, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant...

SCYX : 0.6230 (-1.19%)
Scynexis: Q2 Earnings Snapshot

Scynexis: Q2 Earnings Snapshot

SCYX : 0.6230 (-1.19%)
SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update

First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical hold, triggering a $10M milestone payment from GSK. An additional $20M milestone will be triggered upon the six...

SCYX : 0.6230 (-1.19%)

Business Summary

SCYNEXIS, Inc. is a pharmaceutical company. It is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening...

See More

Key Turning Points

3rd Resistance Point 0.6687
2nd Resistance Point 0.6570
1st Resistance Point 0.6438
Last Price 0.6230
1st Support Level 0.6189
2nd Support Level 0.6072
3rd Support Level 0.5940

See More

52-Week High 1.4900
Fibonacci 61.8% 1.1366
Fibonacci 50% 1.0275
Fibonacci 38.2% 0.9183
Last Price 0.6230
52-Week Low 0.5650

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar